Protagonist Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Protagonist Therapeutics, Inc. announces participation in three upcoming investor conferences in March 2024, including the 2024 Jefferies Biotech on the Bay Summit, 13th Annual Napa Valley Biotech Forum, and H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference.

NEWARK, CA / ACCESSWIRE / March 6, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that they will participate in three upcoming investor conferences:

Event: 2024 Jefferies Biotech on the Bay Summit

Date: March 12-13, 2024
Location: W Hotel South Beach, Miami, FL.

Event: 13^th Annual Napa Valley Biotech Forum

Date: March 26-28, 2024
Presentation: Tuesday, March 26 at 10:30-11:10 A.M. PDT
Location: The J.P. Morgan Office, 560 Mission Street, San Francisco, CA on March 26, and at The Solage Hotel, Calistoga, CA on March 27 - 28.

Event: H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference

Date: March 28, 2024
Fireside Chat: Thursday, March 28, 2024, at 1:00-1:30 P.M. EDT
Location: Virtual

About Protagonist

Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and JNJ scientists jointly discovered PN-235 (now known as JNJ-2113) as part of Protagonist's Interleukin-23 receptor (IL-23R) collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program. The randomized portion of the Phase 2 REVIVE study was unblinded, showing positive results and is now complete, with an open-label extension underway. The global Phase 3 VERIFY study of rusfertide in polycythemia vera is ongoing. Rusfertide will be co-developed and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda entered into in January 2024. The agreement will be effective upon the termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com

Media Relations Contact

Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061

SOURCE: Protagonist Therapeutics, Inc.

View the original press release on accesswire.com

FAQ

What events will Protagonist Therapeutics, Inc. participate in March 2024?

Protagonist Therapeutics, Inc. will participate in the 2024 Jefferies Biotech on the Bay Summit, 13th Annual Napa Valley Biotech Forum, and H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference.

When and where will the 13th Annual Napa Valley Biotech Forum take place?

The 13th Annual Napa Valley Biotech Forum will be held on March 26-28, 2024, with a presentation on Tuesday, March 26 at 10:30-11:10 A.M. PDT at The J.P. Morgan Office, San Francisco, CA, and at The Solage Hotel, Calistoga, CA on March 27 - 28.

What is the date and location of the H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference?

The H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference will take place on March 28, 2024, with a Fireside Chat on Thursday, March 28, 2024, at 1:00-1:30 P.M. EDT in a virtual setting.